Amiodarone-Associated Optic Neuropathy

Amiodarone-Associated Optic Neuropathy: Clinical Review

“…During the observational period, optic neuropathy developed in 17 amiodarone-treated patients (0.3%) and in 30 control patients (0.1%). 24 Multivariate Cox regression analysis showed that amiodarone-treated patients had a 2-fold increased risk of optic neuropathy (hazard ratio = 2.09), especially in males and possibly in patients with longer duration of amiodarone treatment. 24 …”

“…23 On the other hand, we have conducted a retrospective population-based cohort study to investigate whether amiodarone use is associated with an increased risk of optic neuropathy. 24 In this study, 6175 amiodarone newly treated patients and 24,700 age-and gender-matched controls between 2005 and 2009 from Taiwan National Health Insurance Research Database were analysed. During the observational period, optic neuropathy developed in 17 amiodarone-treated patients (0.3%) and in 30 control patients (0.1%).…”

“…6 In Cheng et al's study, among the amiodarone-treated patients, male gender was associated with a nearly 3-fold increased risk of optic neuropathy development compared with female gender. 24 However, there is no sex predilection in NAION. In addition, optic disc swelling in NAION usually resolved within 2 to 6 weeks.…”

Association between nasopharyngeal carcinoma and risk of optic neuropathy: A population‐based cohort study

“…18,19,[21][22][23] Optic neuropathy is diagnosed clinically; visual field testing by either manual kinetic or automated static perimetry is critical. All insurance claims should be scrutinized by medical reimbursement specialists and peer reviewed according to the standard diagnosed criteria in the study.…”

“…18,19 All subjects were followed from the index date until the date of optic neuropathy, withdrawal from the NHI program, or December 31, 2011, whichever occurred first. Diagnosis required the following criteria: (1) an optic neuropathy diagnostic code documented by an ophthalmologist: ICD-9-CM codes 377.0-377.6, 377.9, 950.0, 950.1, 950.2, or 950.9; (2) having undergone a visual field examination; and (3) having undergone a fundus examination, such as a funduscopy, indirect ophthalmoscopy, fundus color photography, or fluorescein angiography.…”